Skip to main content
    E

    Enovis Corp (ENOV)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $27.93
    +0.25 (+0.90%)

    Market Cap: $1.60B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Enovis Corp (ENOV) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Enovis (ENOV) trades at 8.3x trailing earnings and 0.7x sales. Its P/E of 8.3x is below its 5-year median of 13.7x. Its forward P/E is 7.7x. The median P/E across 6 similar companies is 30.5x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 7.8% higher over the next year. Its free cash flow yield is 4.3%.

    MultipleValue
    P/E (trailing)8.3x
    Forward P/E7.7x
    Price to sales0.7x
    Price to book1.1x
    Price to FCF23.2x
    EV/FCF41.9x
    PEG1.9
    FCF yield4.3%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 34.1% below 12.6x.

    MultipleCurrent5-year median10-year median
    P/E8.3x13.7x12.6x
    P/B1.1x0.8xN/A
    Medians of month-end values through Oct 2026: 56 to 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 5.2x in 2018 to 23.6x in 2022.

    Year endPriceP/EP/SP/B
    2025$26.648.1x0.7x1.0x
    2024$43.8815.5x1.2x1.0x
    2023$56.0223.3x1.8x0.9x
    2022$53.5223.6x1.9x0.8x
    2021$79.1212.4xN/AN/A
    2020$65.8215.8xN/A0.5x
    2019$62.629.6xN/AN/A
    2018$35.975.2xN/A0.3x
    2017$68.1913.8x5.0x0.5x
    2016$61.8413.2xN/A1.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ENOV

    What is ENOV's forward P/E ratio?

    Enovis has a forward P/E ratio of 7.7x.

    Is ENOV stock overvalued?

    GNG's valuation label for ENOV is Undervalued. Its P/E of 8.3x compares with a median of 30.5x across 6 similar companies.

    What is ENOV's price to sales ratio?

    Enovis has a price to sales ratio of 0.7x.

    What is Enovis's average P/E ratio over 5 years?

    Enovis's median P/E over the last 5 years is 13.7x, from 60 month-end values through Oct 2026.

    What is ENOV's PEG ratio?

    Enovis has a PEG ratio of 1.9.